Arcturus Therapeutics stock analysis
Want to see ARCT full AI Analyst Report?
The reported potency improvement could enable lower or less frequent dosing and expand the diseases addressable with mRNA medicines. If translated clinically, this platform advancement may strengthen Arcturus’s technology base and support multiple future programs.
Positive biomarker results in a rare metabolic disease program provide clinical validation for Arcturus’s mRNA approach. Continued progress across ARCT-810, ARCT-032, and ARCT-2601 creates several opportunities for future development milestones rather than reliance on one candidate.
A runway through 2028 gives Arcturus time to pursue planned clinical and regulatory milestones without immediate dependence on external financing. Low leverage adds flexibility because the company carries limited debt relative to equity while advancing its pipeline.
The company is not currently self-funding: substantial losses are accompanied by negative operating and free cash flow. Continued spending on development therefore consumes capital, and prolonged unprofitability could eventually reduce financial flexibility despite the current cash runway.
The sharp revenue decline highlights volatility in a business model reliant on collaboration, grant, and milestone-related income. Lower recurring or recognized partner revenue can make funding the pipeline more dependent on future deal activity and successful development events.
Uncertainty around Phase III timing delays clarity on the program’s path toward pivotal development and potential commercialization. Additional data analysis and FDA engagement remain necessary, which could extend development timelines and postpone meaningful economic returns.
In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics, with a price target of $20.00. Thomas Shrader’s rating is based on several factors,
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Arcturus Therapeutics. The associated price target remains the same with $9.00. Andrew Fein has given his Hold rating
The company states: “Arcturus Therapeutics (ARCT) announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase deficiency and introduced LUNAR 2.0, the Company’s next-generation mRNA delivery platform, and additional
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
The call was predominantly positive, with encouraging ARCT-810 clinical data, a reported 38-fold LUNAR 2.0 potency improvement, progress in the ARCT-032 and ARCT-2601 programs, expanding pipeline capabilities and a cash runway through year-end 2028. The main negatives were the significant year-to-date revenue decline, higher year-to-date net loss, reduced cash balance and uncertainty around the timing of a potential ARCT-032 Phase III start.
View all ARCT earnings summaries| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
